

Five-Year Data Report From the Phase 2 PaTH Forward Trial of Palopegteriparatide for Adults With Hypoparathyroidism

Andrea Palermo, MD, PhD¹; Lars Rejnmark, MD, PhD²; Aliya A. Khan, MD³; Peter Schwarz, MD⁴; Lorenz C. Hofbauer, MD⁵; Filomena Cetani, MD, PhD⁶; Rajesh K. Jain, MD⁷; Bart L. Clarke, MD⁸; Carol Zhao, MS⁹; Michael S. Ominsky, PhD⁹; Jenny Ukena, MD⁹; Christopher T. Sibley, MD⁹; Aimee D. Shu, MD⁹; Mishaella R. Rubin, MD¹⁰

¹Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Campus Bio-medico, Rome, Italy and Unit of Endocrinology and Diabetes, Campus Bio-medico University, Rome, Italy;

²Aarhus University Hospital, Aarhus, Denmark; ³McMasterUniversity, Hamilton, ON, Canada;

⁴Rigshospitalet, Copenhagen, Denmark; ⁵Universitätsklinikum Dresden, Dresden, Germany;

⁶Department of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy;

⁷University of Chicago, Chicago, IL, USA; ⁸Mayo Clinic, Rochester, MN, USA; ⁹Ascendis Pharma LLC, Palo Alto, CA, USA; ¹⁰Columbia University, New York, NY, USA

PTH therapy for hypoparathyroidism

- An intact PTH axis maintains normal serum and urine calcium and phosphate homeostasis^{1,2,3}
- PTH is the primary regulator of calcium/phosphate balance, acting directly on bone and kidney, and indirectly on the intestine^{4,5}
- Conventional therapy for hypoparathyroidism (active vitamin D (calcitriol) and oral calcium) aims to alleviate hypocalcemic symptoms but fails to restore normal PTH physiology⁶
- PTH replacement therapy for hypoparathyroidism should provide PTH levels within the physiological range and restore downstream calcitriol, promoting independence from conventional therapy and normalizing:
 - Serum and urine calcium and phosphate
 - Skeletal health
 - Quality of life

PTH, parathyroid hormone





Figure adapted from Shoback D. *N Engl J Med.* 2008;359:391-403.⁷

1. Khan AA, et al. *J Bone Miner Res.* 2022;37:2568-2585. 2. Shoback DM, et al. *J Clin Endocrinol Metab.* 2016;101(6):2300-2312. 3. Bilezikian JP, et al. *J Clin Endocrinol Metab.* 2016;101(6):2313-2324. 4. Mannstadt M, et al. *Nat Rev Dis Primers.* 2017; 3:17055. 5. Brandi ML, et al. *J Clin Endocrinol Metab* 2016;101(6):2273-83. 6. Khan AA, et al. *Eur J Endocrinol.* 2019;180(3):R33-63. 7. Shoback D. *N Engl J Med.* 2008;359:391-403.

Palopegteriparatide (TransCon[®] PTH) design



- Palopegteriparatide is a prodrug of PTH (1-34), administered once daily, that provides active PTH within the physiological range for 24 hours per day^{1,2}
- Palopegteriparatide has received regulatory approval in the US^a, EU^b, and several other countries


PTH, parathyroid hormone; TransCon, transient conjugation.

^a Indicated for the treatment of hypoparathyroidism in adults. ^b Indicated for the treatment of adults with chronic hypoparathyroidism.

1. Karpf DB, et al. *J Bone Miner Res.* 2020;35(8):1430-1440. 2. Holten-Andersen L, et al. *J Bone Miner Res.* 2019;34(11):2075-2086.

Phase 2 PaTH Forward trial design (NCT04009291)

Randomized, double-blind, placebo-controlled trial followed by an open-label extension period in adults with chronic hypoparathyroidism



Select Open-Label Extension Endpoints

- Levels of serum calcium (normocalcemia)
- Independence from conventional therapy (defined as taking no active vitamin D and ≤ 600 mg/day elemental calcium)
- Levels of 24-hour urinary calcium
- Incidence of AEs, SAEs, TEAEs

Skeletal Remodeling, Renal, and PRO Endpoints

- Bone turnover markers (P1NP and CTx)
- Bone mineral density by DXA of the lumbar spine L1-L4, femoral neck, total hip, and distal 1/3 radius
- Renal function as assessed by eGFR
- Hypoparathyroidism Patient Experience Scales (HPES) assessments evaluating symptoms and functional impacts

AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event; P1NP, procollagen type 1 N-terminal propeptide; CTx, C-terminal telopeptide of type 1 collagen; DXA, dual X-ray absorptiometry; eGFR, estimated glomerular filtration rate; PRO, patient-reported outcomes.* Palopegteriparatide 6-60 ug/day and conventional therapy titrated per algorithm to maintain normocalcemia.

Baseline demographics and disease characteristics

	All participants (N = 59)
Age (years), mean (SD)	50 (12)
Sex, n (%) female	48 (81)
Postmenopausal, n (%)	17 (35)
Race, n (%) White	54 (92)
Geographic region, n (%)	
North America	38 (64)
Europe	21 (36)
Cause of hypoparathyroidism, n (%)	
Acquired from neck surgery	47 (80)
Autoimmune disease	1 (2)
Idiopathic disease	11 (19)
Duration of hypoparathyroidism (years), median (range)	9 (1 to 39)
Conventional therapy, mean TDD	
Calcium (mg)	1909
Calcitriol (µg) ^a	0.79
Alfacalcidol (µg) ^b	2.38

SD, standard deviation; TDD, total daily dose. Numbers may not add to 100% due to rounding.

^an = 46 (78%) participants used calcitriol at baseline. ^bn = 13 (22%) participants used alfacalcidol at baseline.


Sustained independence from conventional therapy observed in high proportion of participants

	Total palopegteriparatide
Number of participants continuing through Week 266	56
Normal albumin-adjusted serum calcium, ^a n (%)	49 (88)
Independence from active vitamin D, ^b n (%)	54 (96)
Independence from therapeutic doses of calcium, ^b n (%)	53 (95)


^aNormal albumin-adjusted serum calcium levels defined as 8.3-10.6 mg/dL. ^bIndependence defined as a standing dose of active vitamin D equal to zero and elemental calcium ≤ 600 mg on the day prior to the Week 266 visit. Percentages are calculated based on participants who had data on all criteria.

Consistency of mean serum and urine calcium values observed over 5 years of treatment

Mean Serum Calcium



Mean 24-Hour Urine Calcium




Mean serum calcium values remained within the normal range throughout the trial
24-hour urine calcium normalized within 26 weeks and remained normal through Week 266

Ca, calcium; SE, standard error; ULN, upper limit of normal.

^aThe shaded area represents the normal serum calcium range of 8.3-10.6 mg/dL (2.07-2.64 mmol/L). ^bWeek 18 is captured by unlabeled x axis tick mark. ^cThe ULN for males and females are depicted by teal and light blue lines, respectively.


Durable increase in eGFR through 5 years with palopegteriparatide treatment



The increase in eGFR from baseline was sustained through Week 266, with mean (SE) increase in eGFR of 9.4 (1.9) mL/min/1.73m² for the total population^c

^aAll participants received palopegteriparatide during the open-label extension. ^bSecond (unlabeled) X-axis tick in each figure denotes 4 weeks ^cCalculated according to the Modified Diet in Renal Disease Equation (MDRD): eGFR (mL/min/1.73 m²) = 175 × (serum creatinine mg/dL)^{-1.154} × (age)^{-0.203} × 0.742 [if female] × 1.212 [if Black].
eGFR, estimated glomerular filtration rate; SE, standard error

Mean bone mineral density scores trended towards age- and sex-matched norms




Mean BMD T- and Z-scores declined from elevated baseline levels and stayed within normal limits through Week 266

BMD, bone mineral density; DXA, dual X-ray absorptiometry; SD, standard deviation.

^a T-score reference point: young (30-year-old) Caucasian adult (Kanis JA. *Lancet*. 2002;359:1929–36).

Improvement in PROs with palopegteriparatide treatment sustained through Week 266



Hypoparathyroidism-related physical and cognitive symptoms and impacts on physical functioning and daily life improved with palopegteriparatide treatment and were maintained through Week 266

* P value < 0.0001 when compared versus baseline
PRO, patient-reported outcome; HPES, Hypoparathyroidism Patient Experience Scale.

Safety profile over 5 years of palopegteriparatide treatment

TEAEs during palopegteriparatide treatment, n (%)	Total palopegteriparatide (N = 59)
Serious TEAE	8 (13.6)
Serious treatment-related TEAE	2 (3.4)
Treatment-related TEAE	28 (47.5)
TEAE related to hypercalcemia or hypocalcemia leading to ED/urgent care visit and/or hospitalization	3 (5.1)

Treatment-related TEAEs occurring at a rate of $\geq 5\%$ among all participants (N=59) included:

- Hypocalcaemia (13.6%)
- Headache (11.9%)
- Hypercalcaemia (10.2%)
- Nausea (6.8%)
- Paraesthesia (6.8%)

Most TEAEs were mild or moderate and not related to study drug; no TEAEs led to discontinuation of trial or study drug

ED, emergency department; TEAE, treatment-emergent adverse event.

Palopegteriparatide demonstrated sustained efficacy and safety during the 5-year trial

- Nearly all participants achieved independence^a from therapeutic doses of elemental calcium (95%) and independence from active vitamin D (96%)
- Sustained normalization of 24-hour urine calcium excretion
- Sustained improvements in
 - Renal function
 - Patient-reported outcomes
 - Skeletal dynamics
- Palopegteriparatide was generally well tolerated, with no treatment discontinuation due to treatment emergent adverse events

^a Independence defined as a standing dose of elemental calcium ≤ 600 mg and active vitamin D equal to zero and on the day prior to the Week 266 visit

Disclosures and funding

- Ascendis Pharma and the authors thank the participants, study sites, and investigators who participated in this clinical trial.
- Ascendis Pharma Bone Diseases A/S funded this trial and participated in the trial design, research, analysis, data collection, interpretation of the data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Robert Geist, MD, of Ascendis Pharma.
- Financial arrangements of the authors with companies whose products may be related to this presentation are listed as declared by the authors: **AP:** Consultant for Theramex, Bruno Farmaceutici, Amgen; research funding from Amgen, Shire, Ascendis Pharma; speakers bureau for UCB, Amgen; industry grant from Amgen. **LR:** Research funding from Takeda, Kyowa Kirin International, Ascendis Pharma, and Calcilytix; honoraria from Calcilytix Therapeutics; advisory board for Takeda and Amolyt. **AAK:** Research funding and/or industry grants from Amolyt, Ascendis Pharma, Chugai, Radius, and Takeda; honoraria from and advisory board member for Amgen, Alexion, Ascendis Pharma, and Takeda; travel, accommodations, and expenses from Ascendis Pharma; consulting role for Amgen, Alexion, Amolyt, and Ascendis Pharma; speakers bureau participation for Amgen. **PS:** Stock ownership Novo Nordisk, Ascendis Pharma. **LCH:** Received clinical trial support to his institution from Amolyte, Alexion, Ascendis, and support for ad boards and lectures from Amgen, UCB, Ascendis and BluePrint. **RKJ:** Consulting role for Ascendis Pharma; research funding from Amgen Foundation. **BLC:** Research funding and industry grants from Ascendis and Takeda; advisory board member, consultant, honoraria from Ascendis, Takeda, Entera-Bio, Extend-Bio, Amolyt. **CZ, MSO, JU, CTS,** and **ADS:** Full-time employees of Ascendis Pharma. **MRR:** Study investigator for Takeda, Ascendis Pharma, Amolyt, and Calcilytix; advisory board for Ascendis Pharma, speakers bureau for Ascendis Pharma; consulting for MBX.